SU6656-DataSheet-生命科学试剂-MedChemExpress

Hotline:400-820-3792Inhibitors•ScreeningLibraries•Proteinswww.MedChemESU6656Cat.No.:HY-B0789CASNo.:330161-87-0分⼦式:C₁₉H₂₁N₃O₃S分⼦量:371.45作⽤靶点:Src;FAK;Akt作⽤通路:ProteinTyrosineKinase/RTK;PI3K/Akt/mTOR储存⽅式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性数据体外实验DMSO:20mg/mL(53.84mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制备储备液1mM2.6922mL13.4608mL26.9215mL5mM0.5384mL2.6922mL5.3843mL10mM0.2692mL1.3461mL2.6922mL请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。储备液的保存⽅式和期限：-80°C,6months;-20°C,1month。-80°C储存时，请在6个⽉内使⽤，-20°C储存时，请在1个⽉内使⽤。体内实验请根据您的实验动物和给药⽅式选择适当的溶解⽅案。以下溶解⽅案都请先按照InVitro⽅式配制澄的储备液，再依次添加助溶剂：(为保证实验结果的可靠性，澄的储备液可以根据储存条件，适当保存；体内实验的⼯作液，建议您现⽤现配，当天使⽤；以下溶剂前显⽰的百分⽐指该溶剂在您配制终溶液中的体积占⽐；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的⽅式助溶)1.请依序添加每种溶剂：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥2mg/mL(5.38mM);Clearsolution1/2MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemEBIOLOGICALACTIVITY⽣物活性SU6656Src家族激酶抑制剂，抑制Src，Yes，Lyn，Fyn的IC50分别为280，20，130，170nM。SU6656可抑制FAKY576/577、Y925、Y861位点的磷酸化。SU6656还能抑制p-AKT。体外研究SU6656decreasesphosphorylationofSrcfamilykinases(SFKs)inHNSCCcells[2].体内研究SU6656(2-4mg/kg;i.p.;once)significantlydecreasesischemicpostconditioning(IPoCo)mediatedincreaseinfalldowntime[5].AnimalModel:Swissalbinomalemice[5]Dosage:2,4mg/kgAdministration:Intraperitonealinjection;onceResult:SignificantlydecreasedIPoComediatedincreaseinfalldowntime.户使⽤本产品发表的科研⽂献•CancerRes.2021Jan1;81(1):187-198.•Theranostics.2020Jul9;10(19):8573-8590.•JMedChem.2021Sep3.•BiochimBiophysActaMolBasisDis.2018Nov;1864(11):3824-3836.•JAgricFoodChem.2021Jul29.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].BlakeRA,etal.SU6656,aselectivesrcfamilykinaseinhibitor,usedtoprobegrowthfactorsignaling.MolCellBiol.2000Dec;20(23):9018-27.[2].VeraciniL,etal.ElevatedSrcfamilykinaseactivitystabilizesE-cadherin-basedjunctionsandcollectivemovementofheadandnecksquamouscellcarcinomas.Oncotarget.2014Dec26.[3].WuML,etal.DivergentsignalingpathwayscooperativelyregulateTGFβinductionofcysteine-richprotein2invascularsmoothmusclecells.CellCommunSignal.2014Mar28;12:22.[4].OndrusováL,etal.InhibitionofmTORC1bySU6656,theselectiveSrckinaseinhibitor,isnotaccompaniedbyactivationofAkt/PKBsignallinginmelanomacells.FoliaBiol(Praha).2013;59(4):162-7.[5].KumarA,etal.PharmacologicalinvestigationsonpossibleroleofSrckinasesinneuroprotectivemechanismofischemicpostconditioninginmice.IntJNeurosci.2014Oct;124(10):777-86.[6].LiuXF,etal.AntitumoreffectsofimmunotoxinsareenhancedbyloweringHCKortreatmentwithSRCkinaseinhibitors.MolCancerTher.2014Jan;13(1):82-9.McePdfHeight2/2MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemECaution:Producthasnotbeenfullyvalidatedform